Breaking News

Trials & Filings in Brief: Jan. 9, 2014

By Gil Roth | January 9, 2014

Acasti, AZ, BMS, Celator, DiaMedica, GSK, Intercept, Senesco, Vertex

Phase I
DiaMedica completes MAD trial . . . read more

Senesco begins dosing in new cohort . . . read more

Phase II
Intercept halts NASH trial after hitting primary endpoint . . . read more

Vertex posts initial HCV data . . . read more

Phase III
Celator hits 50% enrollment in AML trial . . . read more

AZ/BMS diabetes drug approved . . . read more

GSK cancer combo get accelerated approval . . . read more

Acasti IND cleared by FDA . . . read more
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials